Vaxart, Inc., Announced An Agreement With Hvivo Services Limited, A Subsidiary Of Open Orphan Plc (Aim: Orph) Under Which Hvivo Will Conduct A Characterization Study And, If Successful, Develop A Human Challenge Model Based On The Omicron Variant Of Sars-Cov-2 With The Intent To Conduct A Subsequent Phase Ii Human Challenge Trial (Hct) Of Vaxart
